These findings highlight the potential of integrating PD-L1(+) CTCs and ctDNA kinetics as synergistic, non-invasive biomarkers for prognostic refinement in the immunotherapy era of HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.